William D. McClellan Jr. - 03 Jan 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role: Director
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: RETA
Transactions as of: 03 Jan 2022
Transactions value $: $3,210
Form type: 4
Filing time: 05 Jan 2022, 15:03:44
Previous filing: 21 Jun 2021
Next filing: 09 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$1.61K	+59		$27.32^*	59	03 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Stock Option (right to buy)	Award	$1.6K	+99		$16.14^*	99	03 Jan 2022	Class A common stock	99	$27.32	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent Restricted Stock Units (RSU), which vest on June 8, 2022, subject to continued service through the vesting date
F2	These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $1,612.50.
F3	The options vest in 2 equal installments on March 10, 2022 and June 10, 2022, subject to continued service through each vesting date.
F4	These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $1,612.50.